Ingrid Jantzen
Inventiva (France) · 7 works · 172 citations · h-index 3
Top works
- The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis
- Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models
- MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment
- The New Generation Pan-Ppar Agonist Iva337 Protects the Liver from Metabolic Disorders and Fibrosis
- Odiparcil is a promising substrate reduction therapy in MPS VI murine model
- Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models
- In vitro and in vivo activity of IVA336, a potential substrate reduction therapy, in mucopolysaccharidosis models